Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1999 Apr;5(2):135-137.
doi: 10.3748/wjg.v5.i2.135.

Experimental study of bioartificial liver with cultured human liver cells

Experimental study of bioartificial liver with cultured human liver cells

Ying-Jie Wang et al. World J Gastroenterol. 1999 Apr.

Abstract

AIM:To establish an extracorporeal bioartificial liver support system (EBLSS) using cultured human liver cells and to study its support effect for fulminant hepatic failure (FHF).METHODS:The liver support experiment of EBLSS consisting of aggregates cultured human liver cells, hollow fiber bioreactor, and circulation unit was carried out in dizhepatic dogs.RESULTS:The viability of isolated hepatocytes and nonparenchymal liver cells reached 96%. These cells were successfully cultured as multicellular spheroids with synthetic technique. The typical morphological appearance was retained up to the end of the artificial liver experiment. Compared with the control dogs treated with EBLSS without liver cells, the survival time of artificial liver support dogs was significantly prolonged. The changes of blood pressure, heart rate and ECG were slow. Both serum ammonia and lactate levels were significantly lowered at the 3rd h and 5th h. In addition, a good viability of human liver cells was noted after 5h experiment.CONCLUSION:EBLSS playing a metabolic role of cultured human hepatocytes,is capable of compensating the function of the liver, and could provide effective artificial liver support and therapy for patients with FHF.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Multicellular spheroids of human hepatocytes and nonparenchymal liver cells. Phase-contrast microscope. × 400
Figure 2
Figure 2
Survival curve in the support and control groups.
Figure 3
Figure 3
Changes of serum ammonia in dizhepatic dogs.
Figure 4
Figure 4
Changes of serum lactate in dizhepatic dogs.

Similar articles

Cited by

References

    1. Nyberg SL, Peshwa MV, Payne WD, Hu WS, Cerra FB. Evolution of the bioartificial liver: the need for randomized clinical trials. Am J Surg. 1993;166:512–521. - PubMed
    1. Hughes RD, Williams R. Use of bioartificial and artificial liver support devices. Semin Liver Dis. 1996;16:435–444. - PubMed
    1. Rozga J, Holzman MD, Ro MS, Griffin DW, Neuzil DF, Giorgio T, Moscioni AD, Demetriou AA. Development of a hybrid bioartificial liver. Ann Surg. 1993;217:502–509; discussion 502-509;. - PMC - PubMed
    1. Bismuth H, Figueiro J, Samuel D. What should we expect from a bioartificial liver in fulminant hepatic failure. Artif Organs. 1998;22:26–31. - PubMed
    1. Sussman NL, Kelly JH. Extracorporeal liver support: cell-based therapy for the failing liver. Am J Kidney Dis. 1997;30:S66–S71. - PubMed